Top Tweets for #Arcalyst

The market's reaction to $CRDL's data releases today can be confusing, especially when positive data doesn't lead to an immediate price increase! Looks the same as post the 8Wks data release, a drop & bounce back after understanding how meaningful the data is vs the #Immunosupressive drug approved by FDA!!! 🟢Marked, rapid, and durable reductions in both pericarditis pain & inflammation were observed in the study, and importantly, these reductions were maintained throughout the 6-month study in a recurrent #pericarditis population with a significant disease burden. 🟢At week 8, 93% (25/27) of patients reported a pain score reduction. 🟢3.7 NRS score reduction at week 8 from 5.8 Base-Line to 2.1 4.3 NRS score reduction at week 26 from 5.8 to 1.5 🟢The median time to resolution or near-resolution of pain (i.e., NRS ≤ 2) was rapid, observed in just 5 days following initiation of CardiolRx treatment 🟢CRP levels for the entire group of patients were reduced from 2.0 mg/dL at baseline to 0.74 and 0.55 at weeks 8 and 26 respectively, with a median time to CRP normalization of 21 days. 🟢 Freedom from recurrence was maintained in 71% (17/24) of patients during the EP when CardiolRx™ was continued and patients were weaned off baseline medications. For those patients experiencing a recurrence the median time to an episode was 7.7 weeks during the EP! 🟢 Number of pericarditis episodes per year was markedly reduced from 5.8 prior to study to 0.9 during the study.